#China #Chengdu #SHINE Technologies #C-Ray Therapeutics #Lu-177

C-Ray and SHINE Technologies: A New Era in Medical Isotope Distribution

C-Ray Therapeutics, a radiopharmaceutical Contract Research Development and Manufacturing Organization (CRDMO) based in Chengdu, China, has recently announced a groundbreaking partnership with SHINE Technologies from Janesville, Wisconsin. This strategic collaboration centers on the exclusive distribution of no-carrier-added lutetium-177 (n.c.a. Lu-177), a vital medical isotope used in targeted radiopharmaceutical therapy (TRT) for cancer treatment, throughout mainland China, excluding existing agreements held by SHINE. This partnership not only marks a significant milestone for both companies but also promises to enhance the quality and availability of cancer treatments in the region.

The Importance of Lu-177 in Oncology

Lutetium-177 is gaining recognition as one of the most effective therapeutic radioisotopes in the field of oncology. Its applications span various types of cancer, including prostate cancer and neuroendocrine tumors, which are notoriously challenging to treat. Lu-177's favorable physical properties, such as its ideal half-life and beta emission characteristics, have made it a cornerstone in the development of modern cancer therapies. However, despite its potential, access to high-quality Lu-177 has been limited by supply chain constraints, particularly within China.

Strengthening Supply Chains

The essence of the partnership lies in C-Ray's capability to utilize its expansive 28,000-square-meter facility in Chengdu to provide comprehensive support services to local radiopharmaceutical developers and healthcare institutions. This facility is equipped to handle isotope conjugation, fill-and-finish processes, and quality control — thus offering a complete, ready-to-use isotopic solution for clients. By combining C-Ray’s local infrastructure with SHINE’s robust supply of n.c.a. Lu-177 from its Cassiopeia facility, one of North America’s largest production sites for this isotope, the partnership aims to ensure a steady and reliable supply chain that meets both Chinese and U.S. regulatory demands.

Leadership Voices on the Collaboration

Haitao Qiao, General Manager of C-Ray Therapeutics, expressed enthusiasm regarding the strategic value this partnership brings. He emphasized that stable multi-source isotope access is not only a competitive advantage for C-Ray but also crucial for maintaining a resilient radiopharmaceutical ecosystem in China. Qiao highlighted their commitment towards improving pipeline continuity for their clients, ultimately enhancing patient outcomes.

On the other hand, Greg Piefer, Founder and CEO of SHINE Technologies, also underscored the significance of this partnership, stating that it demonstrates SHINE's commitment to fulfilling the growing demand for n.c.a. Lu-177 in China while continuing to cater to its U.S. customers. The collaboration aims to enhance treatment options and drive innovations in the field of targeted radioligand therapies.

About SHINE Technologies

SHINE Technologies is a recognized leader in developing next-generation fusion technologies aimed at making energy production safer and more efficient. The company has successfully ventured into medical isotope production, focusing on providing high-quality radioisotopes for various medical applications, including cancer diagnostics and treatment. Beyond this, SHINE is also dedicated to pioneering nuclear waste recycling to promote sustainable nuclear energy solutions, further expanding its impact across multiple sectors.

About C-Ray Therapeutics

C-Ray Therapeutics has established itself as a key player in the radiopharmaceutical industry, offering an extensive range of services. Operating under a Class A Radiation Safety License in China, C-Ray specializes in providing end-to-end solutions for radiopharmaceutical development, from preclinical studies to commercial-grade manufacturing. With experience spanning over 70 projects and multiple radioisotopes, C-Ray is well-equipped to support the increasing demand for advanced therapeutic options in the oncology space.

Conclusion

The partnership between C-Ray Therapeutics and SHINE Technologies represents a forward-thinking alliance set to revolutionize cancer treatment accessibility in China. By addressing supply chain restrictions and ensuring a stable source of n.c.a. Lu-177, these companies are poised to significantly enhance the landscape of targeted cancer therapies, ultimately benefiting patients in need of these life-saving treatments.